RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RVX Analyst Report, CDN$5.85 target http://www.resverloHi KBC.
KBC wrote “Because of the big differences they found in the post hoc analyses they have a decent chance of replicating them”.
I agree, particularly because in the post hoc analysis rvx-208 + Crestor achieved 77% RRR and in the phase 3 the target is only ≥ 30% RRR of MACE and this still results in a very high absolute risk reduction, which after all, is really the bottom line.
I agree with your post hoc vs. replication point.
All the best.
Toinv :)